Amylin and Lilly seek expanded Byetta approval
Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Wednesday they are asking the Food and Drug Administration to expand approval for their type 2 diabetes drug Byetta, which could bolster sales as the companies try to get approval for a new, longer-lasting version of the drug.